Abstract
Acquired clotting factor deficiency encompasses bleeding disorders with diverse causes, including clotting factor inhibitors, liver disease, and disseminated intravascular coagulation. Among these, acquired clotting factor inhibitors are particularly rare and diagnostically challenging. Clinical management focuses on early recognition of bleeding, individualized therapy, and dynamic monitoring. In China, standardized protocols exist for acquired hemophilia A, while reports on other rare inhibitors are limited. Treatment strategies target both hemostasis and inhibitor eradication, with novel therapies for refractory cases. This article integrates clinical cases to provide practical guidance for standardized management.